Fabtech Technologies Limited · NSE:FABTECH
Fabtech Technologies — Q1 FY2026-27 Earnings Presentation
20 slides from Fabtech Technologies's earnings presentation, Jul 28, 2026
Slide 1: Stock exchange covering letter for investor presentation
Date: July 28, 2026 To, National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, Listing Department Bandra Kurla Complex, Floor 25, P J Towers, Bandra (East), Mumbai – 400051 Dalal Street, Mumbai – 400001 Maharashtra, India. Maharashtra, India. Symbol: FABTECH Scrip Code: 5
Slide 2: Fabtech Technologies Limited Q1 FY2026-2027 Investor Presentation
FabtechTechnologiesLimited Q1 FY2026-2027 Investor Presentation
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Fabtech Technologies Limited, (The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall n
Slide 4: Why Turnkey + In-House Manufacturing Matters
Why Turnkey + In-House Manufacturing Matters o In pharmaceutical, biopharma, and healthcare projects, choosing a turnkey partner with in-house Process, Air & Water manufacturing capabilities is no longer a preference, it is a strategic necessity. o Single Accountability, Zero Coordination Risk: One
Slide 5: Global Turnkey Solutions Provider to the Life Sciences & Healthcare Sectors
Global Turnkey Solutions Provider to the Life Sciences & Healthcare Sectors Fabtech Technologies Limited (FTL), the flagship of the Fabtech Group, brings three decades of engineering excellence to deliver start-to-finish turnkey solutions for pharmaceutical, biotech, and healthcare facilities worldw
Slide 6: Quarter at a glance
01 · THE QUARTER Quarter at a glance ₹74.98 Cr ₹7.41 Cr ₹4.21 Cr 46.7%
Slide 7: Read it year on year
01 · THE QUARTER Read it year on year Year on year: the right lens Sequential decline: context matters Revenue up 10.3%, consistent with our growth trajectory Q4 is typically the strongest quarter in EPC businesses Swung from a ₹6.13 Cr loss to a ₹4.21 Cr profit Revenue is recognised on the basis of
Slide 8: Revenue follows execution
02 · REVENUE MODEL Revenue follows execution 01 02 03 04 05 06 Tender Order award Engineering & Procurement Execution & Billing & design delivery recognition Revenue recognition happens at the end of a long execution cycle. A quiet Q1 P&L can coexist with a full and healthy project pipeline. Project
Slide 9: Financial highlights
03 · FINANCIALS Financial highlights Revenue (₹ Cr) 68.01 74.98 +10.3% Contribution margin 37.6% 46.7% +910 bps EBITDA (₹ Cr) (5.27) 7.41 Positive PAT (₹ Cr) (6.13) 4.21 Positive Employee cost (₹ Cr) 10.52 10.22 −2.8% Finance costs (₹ Cr) 1.34 0.84 −35.9%
Slide 10: Why the margin matters
03 · FINANCIALS Why the margin matters What drives the improvement 46.7% Better project selection Procurement efficiency Contribution margin, Q1 FY27 — the highest level we have recorded. Execution quality Scope mix
Slide 11: Becoming local, market by market
04 · MARKETS order book and Pipeline Becoming local, market by market SAUDI ARABIA AFRICA +130% ₹27.93 Cr Turnaround Headwinds ₹17.13 Cr in Q1 FY27 Morocco and Kenya combined Standalone, on a YoY basis Severe regional pressure
Slide 12: Geographic revenue mix
04 · MARKETS Geographic revenue mix 29.6% 27.9% 18.2% 10.0% 9.6% 4.8% Rest of world UAE Saudi Arabia India Kenya Morocco International revenue share of approximately 55%, across a footprint of 60+ countries.
Slide 13: Order book and pipeline
04 · MARKETS Order book and pipeline OPEN ORDER BOOK ₹900+ Cr ₹96.5 Cr ₹8.4 Cr ₹9,300+ Cr ₹3,800+ Cr ₹900+ Cr
Slide 14: The business at a glance
04 · MARKETS The business at a glance Pharmaceutical and life Turnkey EPC, design to delivery Cleanrooms, HVAC, process sciences systems, MEP 12 to 36 months, typical Milestone-based billing 60+ countries across 6 continents
Slide 15: Capital allocation philosophy
05 · CAPITAL Capital allocation philosophy Deployed against execution Acquisitions on fit, not pace Idle capital still earns Reviewed every quarter
Slide 16: Strategic direction
05 · STRATEGY Strategic direction Global expansion Operational excellence Technology adoption People and leadership Capital discipline Biologics and specialty pharma Healthcare infrastructure Regulatory pressure driving China+1 strategies increasing capex accelerating investment in the GCC and facil
Slide 17: Outlook for FY27
05 · OUTLOOK Outlook for FY27 20–25% Q2 steady, H2 stronger Expected YoY organic growth for the current fiscal year, based on the order pipeline and Large-ticket opportunities in Africa business visibility. The focus stays fixed
Slide 18: Building infrastructure. Enabling science. Engineering life.
Building infrastructure. Enabling science. Engineering life. Our aspiration is not simply to become larger. It is to become stronger, more resilient and more admired — an institution that commands trust and stands as a global benchmark in life sciences engineering. NAUSHAD PANJWANI, CHAIRMAN · FABTE
Slide 19: Questions
Q1 FY27 EARNINGS CALL Questions Fabtech Technologies Limited www.fabtechnologies.com investors@fabtechnologies.com
Slide 20: Thank You
WE ARE COMMITTED TO SAVING Fabtech Technologies Limited Registered Office: 715, Janki Center, Off Veera Desai Road, Andheri West, Mumbai 400 053, Maharashtra, India AKMIL Strategic Advisors Private Limited THANK YOU Phone: +91 226 159 2900 Address: Office No. 1011, 10th Floor, Opal Corporate Office:
Fabtech Technologies — Q1 FY2026-27 Earnings Presentation on 6ix